Publications by authors named "Alberto Edison"

Claim this Profile
S
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.
Alexander Rumyantsev, Lixia Wang, Shixia Wang, Tracy Kemp, Alana Wriggins, Edison Alberto

EClinicalMedicine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect effectiveness of a novel SARS-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: A cluster randomised analysis.
Asma Binte Aziz, Jonathan Dewing Sugimoto, Sye Lim Hong, Young Ae You, Lulu Bravo, Edison R Alberto

J Infect· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study.
Renan James Lim, Xiangyan Qiu, Edison Alberto, Maria Rosario Capeding, Josefina Carlos

Clin Exp Vaccine Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edison R Alberto

Hum Vaccin Immunother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Erik Buntinx, Leonardo Brochado, Charissa Borja-Tabora, Charles Y Yu, Edison R Alberto

Vaccine· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.
Josefina Cadorna Carlos, Birkneh Tilahun Tadesse, Charissa Borja-Tabora, Edison Alberto, Michelle C Ylade

Lancet Reg Health West Pac· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
Lulu Bravo, Igor Smolenov, Htay Htay Han, Ping Li, Romana Hosain, Edison R Alberto

Lancet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
Maria Rosario Capeding, Birkneh Tilahun Tadesse, Arijit Sil, Edison Alberto, Deok Ryun Kim

NPJ Vaccines· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial.
Maria Rosario Capeding, Edison Alberto, Jodi Feser, Jessica Mooney, Yuxiao Tang

Vaccine X· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
Maria Rosario Capeding, Arijit Sil, Birkneh Tilahun Tadesse, Tarun Saluja, Samuel Teshome, Edison Alberto

EClinicalMedicine· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
Maria Rosario Capeding, Edison Alberto, Arijit Sil, Tarun Saluja, Samuel Teshome

Vaccine· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
Maria Rosario Capeding, Edison R Alberto, Alain Bouckenooghe, Thelma M Laot, Danaya Chansinghakul

J Infect Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority study.
Maria Rosario Z Capeding, Edison Alberto, Amanda Versteilen, Martina Rauscher, Partha Bagchi

Int J Infect Dis· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority study.
Maria Rosario Z Capeding, Corina Jica, Anna Macura-Biegun, Martina Rauscher, Edison Alberto

Vaccine· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Zulfiqar A Bhutta, Maria Rosario Capeding, Ashish Bavdekar, Elisa Marchetti, Shabina Ariff, Edison Alberto

Lancet Infect Dis· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines.
Nancy Bermal, Leszek Szenborn, Alberto Edison, Marina Hernandez, Jerzy Pejcz

Pediatr Infect Dis J· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Nancy Bermal, Leszek Szenborn, Andrzej Chrobot, Edison Alberto, Patricia Lommel

Pediatr Infect Dis J· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis